Survival Benefits of Ganoderma Lucidum in Early-stage Triple-negative Breast Cancer: A Real World Study

Authors: Baohong Jiang, Na Li, Wei Du, Lijun Zeng, Yuanbin Tang, Lunqi Luo, Hongbo Zhu, and Feng Ye.

Journal: Recent Patents on Anti-Cancer Drug Discovery

Study Design:

• Intervention: Ganoderma lucidum spore powder (GLSP)
• Participants: 72 in the treatment group (GLSP) and 216 in the control group (no GLSP) before propensity score matching. 71 in each group after propensity score matching.
• Duration: Retrospective study
• Outcome Measures: Overall survival (OS) and disease-free survival (DFS)

Summary: This study examined the real-world effects of Ganoderma lucidum spore powder (GLSP) on survival in patients with early-stage triple-negative breast cancer (TNBC). Patients taking GLSP showed significantly improved overall survival and disease-free survival compared to those not taking GLSP, even after adjusting for other factors. This suggests that GLSP may be a promising supplemental treatment for early-stage TNBC.